

AUG. 15. 2005 5:47PM

(3) FISH & RICHARDSON 6175428906

NO. 2681 P. 1

RECEIVED  
CENTRAL FAX CENTER

AUG 15 2005

Attorney's Docket No.: 11692-006US1  
Client's Ref. No.: 158-6US

**OFFICIAL COMMUNICATION FACSIMILE:**

**OFFICIAL FAX NO: (571) 273-8300**

Number of pages including this page 3

Applicant : Klaus Cichutek *et al.*  
Serial No. : 10/089,278  
Filed : October 24, 2002

Art Unit : 1636  
Examiner : Tara L. Garvey


Title : Gene Transfer in Human Lymphocytes Using Retroviral scFV Cell Targeting

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Attached to this facsimile communication cover sheet is Response to Restriction Requirement, faxed this 15<sup>th</sup> day of August, 2005, to the United States Patent and Trademark Office.

Date: August 15, 2005

Respectfully submitted,

  
Rolando Medina, Ph.D., J.D.  
Reg. No. 54,756

Fish & Richardson P.C.  
225 Franklin Street  
Boston, MA 02110  
Telephone: (617) 542-5070  
Fax: (617) 542-8906

21147832.doc

NOTE: This facsimile is intended for the addressee only and may contain privileged or confidential information. If you have received this facsimile in error, please immediately call us collect at (617) 542-5070 to arrange for its return. Thank you.

Attorney's Docket No.: 11692-006US1 / 158-6US

RECEIVED  
CENTRAL FAX CENTER

AUG 15 2005

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Klaus Cichutek *et al.*  
Serial No. : 10/089,278  
Filed : October 24, 2002  
Title : GENE TRANSFER IN HUMAN LYMPHOCYTES USING RETROVIRAL  
SCFV CELL TARGETING

Art Unit : 1636  
Examiner : Tara L. Garvey

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

RESPONSE TO RESTRICTION REQUIREMENT

Responsive to the action mailed July 15, 2005, Applicants elect the invention of Group I.  
The election is made with traverse.

Claims 1-8 (Group I) are directed to cell targeting vectors and the use thereof for gene therapy, vaccination therapy or diagnostics. Claims 9 and 10 (Group VI) are directed to the use of a cell targeting vector of Group I for therapy of T-cell-associated diseases. Groups I and VI are linked to form a single general inventive concept, and thus Applicants respectfully request that claims 1-8 (Group I) and claims 9 and 10 (Group VI) be examined together.

## CERTIFICATE OF TRANSMISSION BY FACSIMILE

I hereby certify that this correspondence is being transmitted by facsimile to the Patent and Trademark Office on the date indicated below.

August 15, 2005  
Date of Transmission

Karen Hector  
Signature

Karen Hector  
Typed or Printed Name of Person Signing Certificate

AUG. 15. 2005 5:47PM

(3) FISH & RICHARDSON 6175428906

NO. 2681 P. 3

Applicant : Klaus Cichutek *et al.*  
Serial No. : 10/089,278  
Filed : October 24, 2002  
Page : 2 of 2

Attorney's Docket No.: 11692-006US1 / 158-6US

No fee is believed to be due. Please apply any charges or credits to Deposit Account  
No. 06-1050.

Respectfully submitted,

Date: 15 August 2005



Rolando Medina, Ph.D., J.D.  
Reg. No. 54,756

Fish & Richardson P.C.  
225 Franklin Street  
Boston, MA 02110  
Telephone: (617) 542-5070  
Facsimile: (617) 542-8906

21143665.doc